Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 18/20 | 1.00 |
| ▸ | SELE | P16581 | 18/20 | 1.00 |
| ▸ | VCAM1 | P19320 | 10/20 | 0.79 |
| ▸ | CCNC | P24863 | 2/20 | 0.79 |
| ▸ | CDK8 | P49336 | 2/20 | 0.79 |
| ▸ | CDC7 | O00311 | 1/20 | 0.73 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.73 |
| ▸ | FYN | P06241 | 1/20 | 0.73 |
| ▸ | CDK1 | P06493 | 1/20 | 0.73 |
| ▸ | PIM1 | P11309 | 1/20 | 0.73 |
| ▸ | PRKACA | P17612 | 1/20 | 0.73 |
| ▸ | CDK2 | P24941 | 1/20 | 0.73 |
| ▸ | FLT4 | P35916 | 1/20 | 0.73 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.73 |
| ▸ | CLK2 | P49760 | 1/20 | 0.73 |
| ▸ | GSK3A | P49840 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055341 | 0.88 | ICAM1 (1.00) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7056161 | 0.88 | CCNC (1.00) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7055338 | 0.88 | ICAM1 (0.79) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7052312 | 0.87 | ICAM1 (0.78) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7057602 | 0.87 | SELE (1.00) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7054707 | 0.87 | CCNC (0.79) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7050646 | 0.86 | ICAM1 (1.00) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7051977 | 0.86 | SELE (1.00) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7253230 | 0.86 | SELE (0.77) | ICAM1SELEVCAM1CCNCCDK8 | |
| SCHEMBL7055764 | 0.85 | ICAM1 (1.00) | ICAM1SELEVCAM1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | claimed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | claimed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | claimed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | claimed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | claimed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | claimed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074932-A1 | THE USE OF (S) - PANTOPRAZOLE MAGNESIUM FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1517706-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | ICAM1 1/4885SELE 16/4885VCAM1 2/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | ICAM1 1/4885SELE 16/4885VCAM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.